Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) EBT Margin (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed EBT Margin for 14 consecutive years, with 87.61% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 4664.0% year-over-year to 87.61%, compared with a TTM value of 91.59% through Dec 2025, down 2944.0%, and an annual FY2025 reading of 2.47%, down 253.0% over the prior year.
  • EBT Margin was 87.61% for Q4 2025 at Karyopharm Therapeutics, down from 58.29% in the prior quarter.
  • Across five years, EBT Margin topped out at 55.76% in Q2 2024 and bottomed at 246.2% in Q1 2021.
  • Average EBT Margin over 5 years is 103.72%, with a median of 98.08% recorded in 2023.
  • The sharpest move saw EBT Margin surged 15962bps in 2022, then tumbled -14805bps in 2025.
  • Year by year, EBT Margin stood at 30.57% in 2021, then tumbled by -474bps to 114.45% in 2022, then decreased by -9bps to 124.32% in 2023, then decreased by -8bps to 134.25% in 2024, then soared by 35bps to 87.61% in 2025.
  • Business Quant data shows EBT Margin for KPTI at 87.61% in Q4 2025, 58.29% in Q3 2025, and 92.28% in Q2 2025.